Every industry has defining moments the ones that separate hype from principle and reveal who’s truly here for the long game. This is one of those moments for ours, and I want to be completely transparent about where we stand. Biomed Industries is the company credited with discovering Bioglutide (NA-931) and developing it as a next-generation GLP-based compound. Our raw materials came from the same supplier Biomed reportedly uses. Recently, serious accusations have surfaced against Biomed claims of fraudulent data, lack of publicly verifiable sequence information, and the absence of a disclosed CAS number or molecular structure. The accuser has raised valid scientific concerns that deserve to be addressed. At the same time, these allegations are new, and Biomed has not yet had the opportunity to publicly respond. That’s why we are pausing not panicking. Even in moments like this, our safeguards remain strong. We can fully document purity through HPLC and LC-MS, confirm sterility and endotoxin levels, and provide verified Certificates of Analysis. However, without a public reference structure or sequence, no lab including ours can confirm 100% molecular identity. We can verify that a compound is clean, sterile, and potent, but we can’t compare it to a molecule that’s never been fully published. To give some context, CB4211 is a great example of how innovation often moves faster than public documentation. This compound, developed for mitochondrial health and metabolic optimization, has been prescribed by physicians and compounded by pharmacies despite its structure, sequence, and CAS never being publicly released. That doesn’t make it ineffective or illegitimate it simply illustrates that, just like Bioglutide, the available data can only go so far. In both cases, these products are sourced, tested, and manufactured to the highest standards, with thorough purity and safety testing but without full structural transparency. That means identity and uniqueness are established through trust, testing, and outcomes rather than public disclosure. For all we know, CB4211 could be a more advanced form or reformulated analog of MOTS-c—or perhaps just a more expensive version under a new label. Until formal sequencing or patent releases are made public, no one can say for sure. This doesn’t discredit its value; it simply reminds us that in early-stage biotech, certainty often trails behind discovery. That’s why rigorous testing, ethical sourcing, and open communication about what is known and what isn’t are so vital.

At AlchemIQ Labs, we don’t just follow the science we help write it. While others speculate, we lead with rigorous research, innovative formulations, and uncompromising integrity. Our mission is simple but bold: to redefine what’s possible in cellular medicine and performance by delivering compounds that actually work, not just buzzwords. Every formula we create is grounded in peer-reviewed science. Biogoutide is a first-in-class oral therapy designed to go beyond standard GLP-1 drugs. Where current treatments often sacrifice muscle or cause harsh GI side effects, Bioglutide leverages a quadruple receptor agonist strategy, activating IGF-1, GLP-1, GIP, and glucagon receptors simultaneously. This synergy creates a powerful metabolic reset: GLP-1 + GIP → enhance insulin secretion, improve glucose control, and suppress appetite at the brain level. Glucagon receptor → boosts fat oxidation and raises energy expenditure. IGF-1 receptor → protects and preserves lean muscle mass while fat is being mobilized. Unlike injectables, Bioglutide is orally bioavailable, and is being researched as a once-daily, and able to cross the blood–brain barrier for central appetite modulation. Clinical Proof In Phase 2 clinical trials (13 weeks, 125 participants): Up to 13.8% body weight reduction at the top dose (150 mg/day).No muscle loss observed a key differentiator from GLP-1 monotherapies. Mild side effects only (nausea, diarrhea in <8%), with no severe adverse events. These results position Bioglutide as a superior alternative to single-pathway GLP-1 drugs like semaglutide and tirzepatide, especially for those prioritizing fat loss without compromising muscle integrity. Why It Matters Current GLP-1 agonists are effective but blunt tools—they drive appetite suppression and weight loss but often at the expense of lean tissue and overall metabolic resilience. Bioglutide changes the game by: Targeting multiple pathways at once for balanced, durable results. Preserving muscle through IGF-1 activation while accelerating fat oxidation.